Twist Bioscience (TWST) Receivables - Other (2019 - 2026)

Twist Bioscience (TWST) has 8 years of Receivables - Other data on file, last reported at $8.4 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $8.4 million, up 469.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.4 million (up 469.08% YoY), and the FY2025 annual result was $290000.0, down 85.72% from the prior year.
• Receivables - Other declined to $8.4 million in Q1 2026 per TWST's latest filing, from $12.3 million in the prior quarter.
• Over five years, Receivables - Other peaked at $12.3 million in Q4 2025 and troughed at $290000.0 in Q3 2025.
• A 5-year average of $4.0 million and a median of $2.8 million in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other soared 694.5% in 2022, then slumped 85.72% in 2025.
• A 5-year view of Receivables - Other shows it stood at $5.3 million in 2022, then slumped by 52.42% to $2.5 million in 2023, then fell by 26.52% to $1.8 million in 2024, then surged by 569.52% to $12.3 million in 2025, then tumbled by 31.75% to $8.4 million in 2026.
• Business Quant data shows TWST's Receivables - Other at $8.4 million in Q1 2026, $12.3 million in Q4 2025, and $290000.0 in Q3 2025.